Vitamin D3 -driven signals for myeloid cell differentiation—Implications for differentiation therapy
Abstract Primitive myeloid leukemic cell lines can be driven to differentiate to monocyte-like cells by 1α,25-dihydroxyvitamin D3 (1,25(OH)2 D3 ), and, therefore, 1,25(OH)2 D3 may be useful in differentiation therapy of myeloid leukemia and myelodysplastic syndromes (MDS). Recent studies have provid...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2010-05, Vol.34 (5), p.553-565 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 565 |
|---|---|
| container_issue | 5 |
| container_start_page | 553 |
| container_title | Leukemia research |
| container_volume | 34 |
| creator | Hughes, Philip J Marcinkowska, Ewa Gocek, Elzbieta Studzinski, George P Brown, Geoffrey |
| description | Abstract Primitive myeloid leukemic cell lines can be driven to differentiate to monocyte-like cells by 1α,25-dihydroxyvitamin D3 (1,25(OH)2 D3 ), and, therefore, 1,25(OH)2 D3 may be useful in differentiation therapy of myeloid leukemia and myelodysplastic syndromes (MDS). Recent studies have provided important insights into the mechanism of 1,25(OH)2 D3 -stimulated differentiation. For myeloid progenitors to complete monocytic differentiation a complex network of intracellular signals has to be activated and/or inactivated in a precise temporal and spatial pattern. 1,25(OH)2 D3 achieves this change to the ‘signaling landscape’ by (i) direct genomic modulation of the level of expression of key regulators of cell signaling and differentiation pathways, and (ii) activation of intracellular signaling pathways. An improved understanding of the mode of action of 1,25(OH)2 D3 is facilitating the development of new therapeutic regimens. |
| doi_str_mv | 10.1016/j.leukres.2009.09.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2847023</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0145212609004706</els_id><sourcerecordid>733838096</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3800-15b9ed1e9f5a69c1695f913102a5743070e80791fe081c4cf3c7b1b36f05b3aa3</originalsourceid><addsrcrecordid>eNpdkU2O1DAQhS0EYpqBI4CyY5WmKm4n9gYJzfAz0kgs-NlajlOecY8TN3bSUu84BCfkJCR0iwGkkizLr55f1cfYc4Q1AtavtutA012ivK4A1HophAdshbLhpZBcPGQrwI0oK6zqM_Yk5y0ACIXqMTtDJRFlVa2Y--pH0_uhuORF2SW_p6HI_mYwIRcupqI_UIi-KyyFUHTeOUo0jN6MPg4_v_-46nfB29-3o_4_STHeUjK7w1P2yM2W9Ox0nrMv795-vvhQXn98f3Xx5rq0XAKUKFpFHZJywtTKYq2EU8gRKiOaDYcGSEKj0BFItBvruG1abHntQLTcGH7OXh99d1PbU2fnIMkEvUu-N-mgo_H635fB3-qbuNeV3DRQ8dng5ckgxW8T5VH3Pi_Dm4HilHXDuZyjqnpWiqPSpphzIvfnFwS9INJbfUKkF0R6KYS578XfEe-7TkzuZ6B5UXtPSdvgh3nL4Y4OlLdxSgsejTpXGvSnhfICGRTAPETNfwFb-6fa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733838096</pqid></control><display><type>article</type><title>Vitamin D3 -driven signals for myeloid cell differentiation—Implications for differentiation therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Hughes, Philip J ; Marcinkowska, Ewa ; Gocek, Elzbieta ; Studzinski, George P ; Brown, Geoffrey</creator><creatorcontrib>Hughes, Philip J ; Marcinkowska, Ewa ; Gocek, Elzbieta ; Studzinski, George P ; Brown, Geoffrey</creatorcontrib><description>Abstract Primitive myeloid leukemic cell lines can be driven to differentiate to monocyte-like cells by 1α,25-dihydroxyvitamin D3 (1,25(OH)2 D3 ), and, therefore, 1,25(OH)2 D3 may be useful in differentiation therapy of myeloid leukemia and myelodysplastic syndromes (MDS). Recent studies have provided important insights into the mechanism of 1,25(OH)2 D3 -stimulated differentiation. For myeloid progenitors to complete monocytic differentiation a complex network of intracellular signals has to be activated and/or inactivated in a precise temporal and spatial pattern. 1,25(OH)2 D3 achieves this change to the ‘signaling landscape’ by (i) direct genomic modulation of the level of expression of key regulators of cell signaling and differentiation pathways, and (ii) activation of intracellular signaling pathways. An improved understanding of the mode of action of 1,25(OH)2 D3 is facilitating the development of new therapeutic regimens.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2009.09.010</identifier><identifier>PMID: 19811822</identifier><language>eng</language><publisher>England</publisher><subject>Calcitriol - pharmacology ; Cell Differentiation - drug effects ; Cell Line, Tumor ; Hematology, Oncology and Palliative Medicine ; Humans ; Leukemia, Myeloid - therapy ; Myeloid Cells - cytology ; Myeloid Cells - drug effects ; Signal Transduction - drug effects ; Signal Transduction - physiology</subject><ispartof>Leukemia research, 2010-05, Vol.34 (5), p.553-565</ispartof><rights>Elsevier Ltd</rights><rights>Copyright (c) 2009 Elsevier Ltd. All rights reserved.</rights><rights>2009 Elsevier Ltd. All rights reserved. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3800-15b9ed1e9f5a69c1695f913102a5743070e80791fe081c4cf3c7b1b36f05b3aa3</citedby><cites>FETCH-LOGICAL-c3800-15b9ed1e9f5a69c1695f913102a5743070e80791fe081c4cf3c7b1b36f05b3aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19811822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hughes, Philip J</creatorcontrib><creatorcontrib>Marcinkowska, Ewa</creatorcontrib><creatorcontrib>Gocek, Elzbieta</creatorcontrib><creatorcontrib>Studzinski, George P</creatorcontrib><creatorcontrib>Brown, Geoffrey</creatorcontrib><title>Vitamin D3 -driven signals for myeloid cell differentiation—Implications for differentiation therapy</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>Abstract Primitive myeloid leukemic cell lines can be driven to differentiate to monocyte-like cells by 1α,25-dihydroxyvitamin D3 (1,25(OH)2 D3 ), and, therefore, 1,25(OH)2 D3 may be useful in differentiation therapy of myeloid leukemia and myelodysplastic syndromes (MDS). Recent studies have provided important insights into the mechanism of 1,25(OH)2 D3 -stimulated differentiation. For myeloid progenitors to complete monocytic differentiation a complex network of intracellular signals has to be activated and/or inactivated in a precise temporal and spatial pattern. 1,25(OH)2 D3 achieves this change to the ‘signaling landscape’ by (i) direct genomic modulation of the level of expression of key regulators of cell signaling and differentiation pathways, and (ii) activation of intracellular signaling pathways. An improved understanding of the mode of action of 1,25(OH)2 D3 is facilitating the development of new therapeutic regimens.</description><subject>Calcitriol - pharmacology</subject><subject>Cell Differentiation - drug effects</subject><subject>Cell Line, Tumor</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Leukemia, Myeloid - therapy</subject><subject>Myeloid Cells - cytology</subject><subject>Myeloid Cells - drug effects</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - physiology</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU2O1DAQhS0EYpqBI4CyY5WmKm4n9gYJzfAz0kgs-NlajlOecY8TN3bSUu84BCfkJCR0iwGkkizLr55f1cfYc4Q1AtavtutA012ivK4A1HophAdshbLhpZBcPGQrwI0oK6zqM_Yk5y0ACIXqMTtDJRFlVa2Y--pH0_uhuORF2SW_p6HI_mYwIRcupqI_UIi-KyyFUHTeOUo0jN6MPg4_v_-46nfB29-3o_4_STHeUjK7w1P2yM2W9Ox0nrMv795-vvhQXn98f3Xx5rq0XAKUKFpFHZJywtTKYq2EU8gRKiOaDYcGSEKj0BFItBvruG1abHntQLTcGH7OXh99d1PbU2fnIMkEvUu-N-mgo_H635fB3-qbuNeV3DRQ8dng5ckgxW8T5VH3Pi_Dm4HilHXDuZyjqnpWiqPSpphzIvfnFwS9INJbfUKkF0R6KYS578XfEe-7TkzuZ6B5UXtPSdvgh3nL4Y4OlLdxSgsejTpXGvSnhfICGRTAPETNfwFb-6fa</recordid><startdate>201005</startdate><enddate>201005</enddate><creator>Hughes, Philip J</creator><creator>Marcinkowska, Ewa</creator><creator>Gocek, Elzbieta</creator><creator>Studzinski, George P</creator><creator>Brown, Geoffrey</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201005</creationdate><title>Vitamin D3 -driven signals for myeloid cell differentiation—Implications for differentiation therapy</title><author>Hughes, Philip J ; Marcinkowska, Ewa ; Gocek, Elzbieta ; Studzinski, George P ; Brown, Geoffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3800-15b9ed1e9f5a69c1695f913102a5743070e80791fe081c4cf3c7b1b36f05b3aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Calcitriol - pharmacology</topic><topic>Cell Differentiation - drug effects</topic><topic>Cell Line, Tumor</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Leukemia, Myeloid - therapy</topic><topic>Myeloid Cells - cytology</topic><topic>Myeloid Cells - drug effects</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hughes, Philip J</creatorcontrib><creatorcontrib>Marcinkowska, Ewa</creatorcontrib><creatorcontrib>Gocek, Elzbieta</creatorcontrib><creatorcontrib>Studzinski, George P</creatorcontrib><creatorcontrib>Brown, Geoffrey</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hughes, Philip J</au><au>Marcinkowska, Ewa</au><au>Gocek, Elzbieta</au><au>Studzinski, George P</au><au>Brown, Geoffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin D3 -driven signals for myeloid cell differentiation—Implications for differentiation therapy</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2010-05</date><risdate>2010</risdate><volume>34</volume><issue>5</issue><spage>553</spage><epage>565</epage><pages>553-565</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><abstract>Abstract Primitive myeloid leukemic cell lines can be driven to differentiate to monocyte-like cells by 1α,25-dihydroxyvitamin D3 (1,25(OH)2 D3 ), and, therefore, 1,25(OH)2 D3 may be useful in differentiation therapy of myeloid leukemia and myelodysplastic syndromes (MDS). Recent studies have provided important insights into the mechanism of 1,25(OH)2 D3 -stimulated differentiation. For myeloid progenitors to complete monocytic differentiation a complex network of intracellular signals has to be activated and/or inactivated in a precise temporal and spatial pattern. 1,25(OH)2 D3 achieves this change to the ‘signaling landscape’ by (i) direct genomic modulation of the level of expression of key regulators of cell signaling and differentiation pathways, and (ii) activation of intracellular signaling pathways. An improved understanding of the mode of action of 1,25(OH)2 D3 is facilitating the development of new therapeutic regimens.</abstract><cop>England</cop><pmid>19811822</pmid><doi>10.1016/j.leukres.2009.09.010</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2010-05, Vol.34 (5), p.553-565 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2847023 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Calcitriol - pharmacology Cell Differentiation - drug effects Cell Line, Tumor Hematology, Oncology and Palliative Medicine Humans Leukemia, Myeloid - therapy Myeloid Cells - cytology Myeloid Cells - drug effects Signal Transduction - drug effects Signal Transduction - physiology |
| title | Vitamin D3 -driven signals for myeloid cell differentiation—Implications for differentiation therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T20%3A14%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20D3%20-driven%20signals%20for%20myeloid%20cell%20differentiation%E2%80%94Implications%20for%20differentiation%20therapy&rft.jtitle=Leukemia%20research&rft.au=Hughes,%20Philip%20J&rft.date=2010-05&rft.volume=34&rft.issue=5&rft.spage=553&rft.epage=565&rft.pages=553-565&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2009.09.010&rft_dat=%3Cproquest_pubme%3E733838096%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733838096&rft_id=info:pmid/19811822&rft_els_id=1_s2_0_S0145212609004706&rfr_iscdi=true |